Key result
Intravenous morphine use in acute coronary syndrome is associated with delayed antiplatelet absorption, larger infarct sizes, and potentially increased mortality across multiple reviewed studies.
Why the study?
Does intravenous morphine increase adverse outcomes in patients with acute coronary syndrome?
Does intravenous morphine increase adverse outcomes in patients with acute coronary syndrome?
Intravenous morphine for chest pain in ACS may lead to delayed antiplatelet absorption and larger infarct sizes, challenging its routine use as recommended by current guidelines.
Answers are grounded in this paper and cite their sources.
May warrant caution with IV morphine in ACS; leaves open need for RCTs on hard outcomes.
Chest pain in acute coronary syndrome (ACS) unresponsive to nitrates is routinely treated by intravenous (IV) morphine. In the past two decades, several studies have emerged, suggesting poorer outcomes in patients receiving this treatment; however, morphine remains the drug of choice for these patients as per the American College of Cardiology/American Heart Association guidelines on ACS management. The results of various studies that examined the impact of morphine on myocardial infarct size, antiplatelet therapy absorption time, and patient mortality are discussed. There is mounting evidence suggesting that morphine may increase adverse events in ACS patients, therefore, the development of more precise criteria for IV morphine administration in ACS patients is needed.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2018) conducted a review in Acute Coronary Syndrome. Intravenous morphine vs. No morphine or placebo was evaluated. Intravenous morphine use in acute coronary syndrome is associated with delayed antiplatelet absorption, larger infarct sizes, and potentially increased mortality across multiple reviewed studies.
Synapse has enriched 10 related papers. Consider them for comparative context: